Elliott P J, Walsh D M, Close S P
Department of Neuropharmacology, Glaxo Group Research Ltd., Ware, Hertfordshire, UK.
Neurosci Lett. 1992 Aug 3;142(1):1-4. doi: 10.1016/0304-3940(92)90606-8.
In a modified MPTP model of Parkinson's disease in the marmoset, both L-DOPA and the dopamine D2 agonist quinpirole were found to exhibit anti-bradykinetic activity. Both the dopamine D1 agonist SKF38393 and the D1 antagonist SCH23390 reduced the anti-bradykinetic action of L-DOPA and quinpirole. These results are discussed with respect to partial agonist activity of SKF38393 and the possibility that other dopamine receptors may be required for anti-Parkinsonian drug activity.